Nanoparticles for Protein Sensing in Primary Containers: Interaction Analysis and Application
Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Advancements and Applications in Nanoparticle Synthesis Through Laser Ablation in Liquids
Published on: June 16, 2023
Víctor Pérez Medina Martínez1, Carlos E Espinosa-de la Garza1, Diego A Méndez-Silva1,2
1Unidad de Investigación y Desarrollo, Probiomed, S.A. de C.V, Cruce de carreteras Acatzingo-Zumpahuacán S/N, C.P. 52400, Tenancingo, Estado de México, México.
Abstract:
Silver nanoparticles (AgNPs) are known to interact with proteins, leading to modifications of the plasmonic absorption that can be used to monitor this interaction, entailing a promising application for sensing adsorption of therapeutic proteins in primary containers. First, transmission electron microscopy in combination with plasmonic absorption and light scattering responses were used to characterize AgNPs and protein-AgNP complexes, including its concentration dependence, using two therapeutic molecules as models: a monoclonal antibody (mAb) and a synthetic copolymer (SC). Upon interaction, a protein corona was formed around AgNPs with the consequent shifting and broadening of their characteristic surface plasmon resonance (SPR) band (400 nm) to 410 nm and longer wavelenghts. Additional studies revealed secondary and three-dimensional structure modifications of model proteins upon interaction with AgNPs by circular dichroism and fluorescence techniques, respectively. Based on the modification of the SPR condition of AgNPs upon interaction with proteins, we developed a novel protein-sensing application of AgNPs in primary containers. This strategy was used to conduct a compatibility assessment of model proteins towards five commercially available prefillable glass syringe (PFS) models. mAb- and SC-exposed PFSs showed that 74 and 94% of cases were positive for protein adsorption, respectively. Interestingly, protein adsorption on 15% of total tested PFSs was negligible (below the nanogram level). Our results highlight the need of a case-by-case compatibility assessment of therapeutic proteins and their primary containers. This strategy has the potential to be easily applied on other containers and implemented during early-stage product development by pharmaceutical companies and for routine use during batch release by packaging manufacturers.
Related Concept Videos
piRNA - Piwi-interacting RNAs
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Introduction to Special Senses
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Predator-Prey Interactions
Tactile and Chemical Senses

